Take action receives UK MHRA clearance for hESC-derived RPE cell trial for Stargardt’s Macular Dystrophy Advanced Cell Technology, Inc. ;, a leader in neuro-scientific regenerative medicine, announced today that it has received clearance from the U.K Click to see more . Medicines and Healthcare products Regulatory Company to begin treating patients as part of a Phase 1/2 scientific trial for Stargardt’s Macular Dystrophy using retinal pigment epithelium produced from human embryonic stem cells . ACT received similar approval from the Gene Therapy Advisory Committee , which includes responsibility for the ethical oversight of proposals to carry out medical trials involving gene or stem cell therapies in the U.K.
By age group 85, the probability of developing the dreaded neurological disorder is 50 % roughly. But researchers at the University of California, NORTH PARK School of Medication say Advertisement hits hardest among the ‘younger elderly’ – people within their 60s and 70s – who show faster prices of brain tissue loss and cognitive decline than AD sufferers 80 years and older. The findings, in the August 2 reported online, 2012 issue of the journal PLOS One, have profound implications for both diagnosing AD – which currently afflicts an estimated 5.6 million Americans, a true number projected to triple by 2050 – and initiatives to find new treatments. There is no cure for AD and existing therapies usually do not gradual or stop disease progression.